SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 32.04 |
| Enterprise Value ($M) | 16.89 |
| Book Value ($M) | 56.13 |
| Book Value / Share | 5.54 |
| Price / Book | 0.57 |
| NCAV ($M) | 6.85 |
| NCAV / Share | 0.68 |
| Price / NCAV | 4.68 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.21 |
| Return on Assets (ROA) | -0.15 |
| Return on Equity (ROE) | -0.18 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.01 |
| Current Ratio | 6.01 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 16.06 |
| Assets | 65.35 |
| Liabilities | 9.21 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Hirschman Orin |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 5,104 | 20,267 | 25.18 | |
| 6,360 | 34,894 | 18.23 | |
| 2,798 | 31,616 | 8.85 | |
| 28,590 | 219,621 | 13.02 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GNLX – Genelux Corporation | GNPX – Genprex, Inc. |
| GOVX – GeoVax Labs, Inc. | GTBP – GT Biopharma, Inc. |
| GYRE – Gyre Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io